Shilpa Medicare Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Record EBITDA, but margin caution: EBITDA hit a quarterly high of INR98 crores (30% margin), yet management explicitly warned that the 700 bps gross margin jump includes lumpy high-margin products and is not a sustainable run-rate.
• Biologics inflection begins: The segment jumped from INR10 crores to INR37 crores QoQ on new CDMO deals and licensing income, with the first biosimilar (Nivolumab) entering human studies by Q4.
• NorUDCA is the near-term catalyst: The first NCE developed by Shilpa, a first-in-India liver health molecule, launches by October with orders from three top-10 IPM partners already in place.
• Debt cost is falling, not debt: The INR550 crores debt is refinanced high-cost paper, not repaid; finance costs dropped YoY but a EUR swap M-to-M hit added INR6.5 crores this quarter.
• What to watch next quarter: The NorUDCA launch trajectory, whether the biologics revenue run-rate holds or grows, and any FDA surprise inspection at the formulation plant.

The NorUDCA Opportunity

• First-mover NCE: Nor-Ursodeoxycholic acid is the first NCE developed by Shilpa and the first global launch of this molecule, targeting liver health and NAFLD directly rather than symptomatically.
• Commercial architecture set: Marketing authorization from central authorities is in hand; state-level licensing is a 15-20 day process with artwork completion pending, putting launch on track for October.
• Partnered for reach: Three of the top 10 IPM companies have signed on for commercialization, plus Shilpa retained its own license, so four entities will launch simultaneously with launch orders already placed.
• Milestone income ahead: Milestone payments are expected within 6 months and 1 year of sales, layered on top of commercial revenue from API supply and profit share.

Keshav Bhutada: "It's one of its kind of molecule approved in India till date, which mainly works on liver health activity, which directly targets liver health and then thereby cures NAFLD."

Biologics & Biosimilars Pipeline

• Revenue jump driven by CDMO and licensing: The INR27 crore QoQ increase came from new CDMO deals signed this quarter, existing CDMO contracts, and licensing income from the Orion recombinant human albumin partnership. Major biosimilar product revenue is still ahead.
• Nivolumab leads the biosimilar charge: The first biosimilar targeting Europe and US markets, with human studies starting by Q4 FY26. Management noted a regulatory tailwind: India clinical studies may now be accepted by European agencies, shortening the path to global markets.
• Albumin partnership advancing: The Orion deal for recombinant human albumin in Europe has cleared clinical study design alignment with the EU agency; Phase III starts by Q4 FY26 or early Q3, with commercial launch expected end-FY28 or early FY29. A US clinical strategy submission goes to the FDA in Q3, with a response expected by Q4.
• Aflibercept on deck: Phase III for India and ROW markets completes this financial year, with commercialization targeted for next year.
• NBE programs funded externally: Alveolus Bio and mAbTree agreements cover start-to-end development and manufacturing, with Shilpa as exclusive clinical trial supplier. Both are expected to enter Phase I in FY27 with no significant change in Shilpa's expenditure.

Keshav Bhutada: "For biosimilars, we were first trying to do India study, and then we were going global. But recently, there are a lot of changes in the clinical study requirements globally. And there is good chance that whatever study we will be doing in India, with the same study, even Europe will accept that study."

Margin Quality & Sustainability

• The 700 bps gross margin jump is not all recurring: The move to 76% gross margin included profit share, licensing fees, and significantly higher-margin products that are quarter-specific. Management explicitly stated this should not be treated as guidance.
• Captive API consumption is the structural margin driver: INR40-odd crores of API was consumed captively this quarter, and that figure is expected to grow QoQ as NorUDCA, Nilotinib, and Axitinib are used for own formulations, particularly in oncology where sustainable growth lives.
• Finance cost has two stories: The underlying interest cost fell by INR1.5 crores QoQ after replacing a high-cost INR75 crore NCD with lower-cost debt. But a EUR interest swap loan generated a INR6.5 crore mark-to-market hit from euro appreciation, pushing the reported finance cost to INR19 crores from INR14 crores QoQ.
• Tax rate was a one-time benefit: The 5.5% effective tax rate came from NCLT approval of the INM Technologies amalgamation, which brought unabsorbed losses onto Shilpa's books. This is not a recurring rate.

Alpesh Dalal: "This margin improvement that has come in, at times, in certain quarters, you do have significantly higher-margin products going in. But obviously, that's not something we would say as a guidance should continue to be considered."

API & Formulation Growth Engines

• API growth is broad-based: The 8% YoY growth to INR187 crores came from portfolio rationalization and improved offtake from newly expanded capacities, with management positive on good growth across oncology, non-oncology, CDMO, peptides, and polymers in upcoming quarters.
• Oncology API pipeline filling: Palbociclib validation batches are complete with DMF filing in 3 months; Olaparib validation batches started and complete by October, then 6-month stability before filing; Teriflunomide formulation is complete with API already commercialized.
• Peptide order book visible: Desmopressin and Octreotide Acetate are commercialized with a strong Desmopressin order book for the next 2 quarters, supplying customers in Europe, US, and ROW. Value is expected to increase next year as customers move to initial commercial quantities.
• Formulation growth from ROW and Europe: INR98 crores in formulation revenue was driven by ROW and European businesses, with ROW growth coming from a mix of products registered over the last 3 years.
• Three NDA molecules contributing this year: Pemetrexed is gaining market share with profit share expected in subsequent quarters; Bortezomib launched recently and is expected to ramp faster based on the Pemetrexed experience.

CDMO & Specialty Pipeline

• Two NCE commercializations in FY27: A gall bladder indication product filed by a US partner (API supply only) and Unicycive (OLC) will both commercialize next financial year. The Unicycive delay of one year was due to a CMO partner's facility issue, not Shilpa's.
• Polymer business building steadily: Commercial supplies started in Q1 for an MNC project, expected to complete by 2H FY26, with a replenishment order to follow and steady business for the next few years. A second specialty polymer for a big pharma customer was developed and supplied this quarter.
• GLP-1 peptide progress: Liraglutide formulation registration batches complete by end of September, with API and formulation filings in global markets after 6-month stability. Semaglutide registration batches start in Q3 FY26. Tirzepatide scale-up begins in Q3 FY26.
• Rotigotine patch nearing milestones: European approval expected in 2H FY26; US filing planned for Q3 FY26 with clinical studies completing soon. The transdermal patch facility already received a US FDA EIR.
• CDMO reporting still in progress: Management is working on consolidating CDMO revenue across FDF, API, and Biologics for separate disclosure, expected to begin in upcoming quarters.

Keshav Bhutada: "Even if FDA asks them to submit with 1-year stability data, they will be submitting it in next year. And once that is submitted, we can surely get the commercialization, or we can likely get the commercialization in next financial year itself because all the GMP data, clinical data is already reviewed by the agency."

Capital & Balance Sheet

• Bonus issue to improve liquidity: The 1:1 bonus was proposed because the equity base is small (under 10 crore shares) and management wants to improve stock liquidity as investor interest grows.
• Debt refinanced, not retired: The INR550 crores of debt as of June 30 represents replacement of high-cost debt with lower-cost facilities, not repayment. The NCD replacement should further reduce interest costs going forward.
• Capex decision pending: Additional capex for the API business is under evaluation, with a final plan expected this quarter and a clearer picture in the next quarterly call. Global clinical studies are not expected to significantly change expenditure because each asset will be partnered at the right time.

Alpesh Dalal: "I think what we believe is that the way the company is growing, the current equity base is small. There are less than 10 crore shares on the market. And the way the interest in the company has been increasing... improving the liquidity of the stock is an important aspect."

Guidance & Commitments

Key Metrics